Page last updated: 2024-12-09

rosaramicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

rosaramicin: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

rosaramicin : A macrolide antibiotic with activity against Neisseria gonorrhoeae, Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma hominis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6537204
CHEMBL ID8965
CHEBI ID87084
MeSH IDM0167577

Synonyms (45)

Synonym
antibiotic m 4365a2
rosaramicin
cirramycin a1, 4'-deoxy-
sch 14947
nsc-175150
m 4365a2
m-4365a2
stereoisomer of 3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-9-((3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl)oxy)-4,17-dioxabicyclo(14.1.0)heptadec-14-ene-10-acetaldehyde
3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-9-((3,4,6-tridesoxy-3-dimethylamino-beta-o-xylo-hexopyranosyl)oxy)-4,17-dioxabicyclo(14.1.0)heptadec-14-en-10-acetaldehyd
juvenimicin a3
rosaramicinum [inn-latin]
rosaramicina [inn-spanish]
4'-deoxycirramycin a(sub 1)
einecs 252-742-1
4,17-dioxabicyclo(14.1.0)heptadec-14-ene-10-acetaldehyde, 3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-9-((3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl)oxy)-
nsc 175150
antibiotic 67-694
rosaramicine [inn-french]
cirramycin a(sub 1), 4'-deoxy-
rosamicin, from micromonospora rosaria, ~98%
4'-deoxycirramycin a1
CHEMBL8965
chebi:87084 ,
sch-14947
2-[(1s,2r,3r,7r,8s,9s,10r,12r,14e,16s)-9-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl]acetaldehyde
rosaramicin [usan:inn:ban]
rosaramicine
unii-e907bnq7sh
rosaramicina
rosaramicinum
e907bnq7sh ,
antibiotic t-1124c
rosaramicin [mart.]
rosaramicin [usan]
antibiotic m-4365a2
rosaramicin [mi]
rosaramicin [inn]
IUPCWCLVECYZRV-JZMZINANSA-N
(1s,2r,3r,7r,8s,9s,10r,12r,14e,16s)-3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl 3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranoside
2-((1s,2r,3r,7r,8s,9s,10r,12r,16s,e)-9-((2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yloxy)-3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl)acetaldehyde
Q7367362
gtpl10855
antibiotic 67694
sch14947
AKOS040747422

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"0 mg kg(-1) established according to the reported lowest dosage of additive needed to lead a growth promoting effect."( Sample preparation strategy for the simultaneous determination of macrolide antibiotics in animal feedingstuffs by liquid chromatography with electrochemical detection (HPLC-ECD).
González de la Huebra, MJ; Vincent, U; von Holst, C, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
macrolide antibioticA macrocyclic lactone with a ring of twelve or more members which exhibits antibiotic activity.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
enoneAn alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position.
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
aldehydeA compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID21658Calculated partition coefficient (clogP)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID19425HPLC capacity factor (k)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID23733Calculated partition coefficient (clogP)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID117681Protective dose at which 50% of infected, treated mice survive1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID26629Dissociation constant (pKa)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID19662Calculated partition coefficient (clogP)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID155774Minimum inhibitory concentration required to inhibit Pasteurella multocida 59A006 in vitro1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Repromicin derivatives with potent antibacterial activity against Pasteurella multocida.
AID155915Minimum inhibitory concentration against Pasteurella multocida.1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID19403Calculated partition coefficient (logD)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID117678Protected dose which protects 50% of challenged mice from death owing to the Pasteurella multocida (59A006) infection1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Repromicin derivatives with potent antibacterial activity against Pasteurella multocida.
AID23096The negative logarithm of the fraction of neutral molecules1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID24865The negative logarithm of the fraction of singly charged molecules.1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (35.00)18.2507
2000's3 (15.00)29.6817
2010's8 (40.00)24.3611
2020's2 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (95.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]